Skip to main content
. 2022 Mar 15;3(2):100101. doi: 10.1016/j.xhgg.2022.100101

Figure 2.

Figure 2

Histology and immunohistochemistry of PIK3CA and BRAF mutated LMs

LM tissue from two individuals with BRAF p.Val600Glu substitutions (A–F) and one individual with PIK3CA p.His1047Arg substitution.

(G–I). H&E stains (A), (D), and (G) show dilated cystic channels with bland, flattened epithelium. (B), (E), and (H) show presence of podoplanin (a.k.a. D2-40) immunoreactivity in endothelial cells. Panels on the right show BRAF p.Val600Glu immunoreactivity (VE1 staining) in endothelial cells in BRAF mutant LM (C and F), but not in PIK3CA mutant LM (I).